Senate Work On Biosecurity Issues Continues Even As House Is Current Focus Of Legislative Activity

US FDA Principal Deputy Commissioner Namandjé Bumpus recently attended a biotech-themed roundtable with the Senate Select Committee on Intelligence and national security officials as Congress’ pulls the FDA into its worries about Chinese influence of the pharma industry.

China v. USA
US lawmakers want to limit China's influence over the pharmaceutical industry. • Source: Shutterstock

The center of political attention in the debate on decoupling US biopharma companies from China shifted away from the Senate after the Homeland Security and Government Affairs Committee advanced the BIOSECURE Act in March. But another committee appears to have continued activities on the topic, and has brought the Food and Drug Administration more directly into the issue.

FDA Principal Deputy Commissioner Namandjé Bumpus was called before members of the Senate Select Committee on Intelligence last month, alongside...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from China

More from Asia